NCT00613067

ERP N1 as a Treatment Predictor of Generalized Anxiety Disorder

The Amplitude Change of the Auditory Evoked N1 Component as a Predictor of Response to Escitalopram Treatment in Patients With Generalized Anxiety Disorder

• Status: Completed
• Phase: N/A
• Study type: Interventional
• Enrollment: 35 (estimated)
• Sponsor: Inje University · Academic / Other
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

Amplitude changes of the N1 and the N1/P2 ERP component in response to different tone intensities have been suggested as a correlative of central serotonergic activity. A strong loudness dependence amplitude increase (strong intensity dependence) reflects low serotonergic neurotransmission and vice versa. Many researchers assumed that the brain serotonergic activity could influence treatment response of highly selective serotonin reuptake inhibitors in depression and anxiety disorders. There are a couple of studies reporting associations of N1 amplitude intensity dependence with response to Citalopram (positive correlation) and Reboxetine (negative correlation) treatment in major depressive disorder patients. But so far there have been no reports about associations between ERP N1 and antidepressant response in GAD patients. So, it would be very interesting to explore the correlations between ERP N1 amplitude change and the Escitalopram treatment responsiveness in GAD patients.

Conditions

• Generalized Anxiety Disorder

Interventions

Type	Name	Description
DRUG	escitalopram	* Start with escitalopram 10mg * According to patient's symptoms, stay on 10mg or increase up to 20mg * Concomitant therapy : up to Xanax 0.5mg, or Ativan 1mg, not allowed above these dosages * Length of washout period will be at least 2 weeks for any psychotropic drugs

Timeline

• Start date: 2007-12-01
• Primary completion: 2010-04-01
• Completion: 2010-05-01
• First posted: 2008-02-12
• Last updated: 2010-06-30

Locations

1 site across 1 country: South Korea